Bispecific antibodies seem to be all the rage at the minute. Their ability to deliver targeted therapeutics to patients with a two-in-one approach by simultaneously binding to two different antigens ...

While bispecific antibodies tend to be well-tolerated for patients with multiple myeloma, there are still adverse effects clinicians should discuss with their patients. The use of bispecific ...

The bispecific antibodies market continues to grow due to the use of BsAbs in diagnostics. In general, bsAb is designed to bind a specific antigen and a detection moiety (e.g., horseradish peroxidase) ...

This approval makes the bispecific antibody the first HER2-targeted treatment to carry the indication. Zanidatamab binds two separate regions on the HER2 cell surface protein, crosslinking ...

A bispecific antibody has entered the HER2 fray with a differentiated profile from traditional agents and a chance to challenge AstraZeneca and Daiichi Sankyo’s star antibody-drug conjugate Enhertu.

The follow-on bispecific antibody ATOR-4066 is in preclinical testing. Alligator has a proprietary technology platform, comprised of two antibody libraries, ALLIGATOR-GOLD® and ALLIGATOR-FAB ...

MSD has an extensive pipeline in oncology but hasn't been a player in bispecific antibodies. Now, it has bolted on a bispecific via a $1.3 billion licensing deal with Curon Biopharma. The big ...

Video content above is prompted by the following: This presentation is to do a deep dive into the operationalization of bispecific antibody (BsAb) therapy in community practices. Please summarize the ...

Johnson & Johnson has agreed a $850 million deal to acquire Proteologix that will give it a pair of early-stage bispecific antibodies with immunology applications, including a drug heading for ...

NEW YORK – Marengo Therapeutics' bispecific antibody, invikafusp alfa, showed potential as treatment for certain cancer patients who have become resistant to checkpoint inhibitors in an early-phase ...

Today, Merck announced that it will acquire LaNova Medicines’ PD-1/VEGF bispecific antibody, LM-299, for $588 million upfront plus financial awards that could reach $2.7 billion if certain development ...

BioNTech will pay Biotheus an upfront consideration of $800 million, predominantly in cash, with a small portion in American depositary shares, plus additional performance-based contingent payments of ...